You are here

HCV Treatment in 2016: Genotypes 1, 2, and 3

Objectives

  • List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
  • Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
  • Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Add comment

Log in to post comments